The impact of bone turnover marker on medication adherence and the health economics-related consequences

References

• Kanis JA, Cooper C, Rizzoli R, et al. Executive summary of the European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Calcif Tissue Int. 2019 Mar;104(3):235–238.
   PubMed Web of Science ®Google Scholar
• Rabenda V, Reginster JY. Overcoming problems with adherence to osteoporosis medication. Expert Rev Pharmacoecon Outcomes Res. 2010 Dec;10(6):677–689. doi: 10.1586/erp.10.76
   PubMed Web of Science ®Google Scholar
• Fatoye F, Smith P, Gebrye T, et al. Real-world persistence and adherence with oral bisphosphonates for osteoporosis: a systematic review. BMJ Open. 2019 Apr 14;9(4):e027049. doi: 10.1136/bmjopen-2018-027049
   PubMed Web of Science ®Google Scholar
• Koller G, Goetz V, Vandermeer B, et al. Persistence and adherence to parenteral osteoporosis therapies: a systematic review. Osteoporosis Int. 2020 Nov;31(11):2093–2102.
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Rabenda V, Gathon HJ, et al. Potential clinical and economic impact of nonadherence with osteoporosis medications. Calcif Tissue Int. 2010 Mar;86(3):202–210. doi: 10.1007/s00223-009-9329-4
   Web of Science ®Google Scholar
• Kanis JA, McCloskey EV, Johansson H, et al. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23–57.
   PubMed Web of Science ®Google Scholar
• Fontalis A, Eastell R. The challenge of long-term adherence: the role of bone turnover markers in monitoring bisphosphonate treatment of osteoporosis. Bone. 2020 Jul 1;136. doi: 10.1016/j.bone.2020.115336
   PubMed Web of Science ®Google Scholar
• Vasikaran S, Eastell R, Bruyère O, et al. Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporosis Int. 2011 Feb;22(2):391–420. doi: 10.1007/s00198-010-1501-1
   PubMed Web of Science ®Google Scholar
• Clowes JA, Peel NFA, Eastell R. The impact of monitoring on adherence and persistence with antiresorptive treatment for postmenopausal osteoporosis: a randomized controlled trial. J Clin Endocrinol Metab. 2004 Mar;89(3):1117–1123. doi: 10.1210/jc.2003-030501
   PubMed Web of Science ®Google Scholar
• International Osteoporosis Foundation and European Calcified Tissue Society Working Group, Diez-Perez A, Naylor KE, et al. Recommendations for the screening of adherence to oral bisphosphonates. Osteoporos Int. 2017 Mar 1;28(3):767–774. doi: 10.1007/s00198-017-3906-6
   PubMed Web of Science ®Google Scholar
• Hiligsmann M, Salas M, Hughes DA, et al. Interventions to improve osteoporosis medication adherence and persistence: a systematic review and literature appraisal by the ISPOR medication adherence & persistence special interest group. Osteoporosis Int. 2013 Dec;24(12):2907–2918.
   PubMed Web of Science ®Google Scholar
• Migliorini F, Maffulli N, Spiezia F, et al. Biomarkers as therapy monitoring for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021 May 18;16(1):318. doi: 10.1186/s13018-021-02474-7
   PubMed Web of Science ®Google Scholar
• Migliorini F, Maffulli N, Spiezia F, et al. Potential of biomarkers during pharmacological therapy setting for postmenopausal osteoporosis: a systematic review. J Orthop Surg Res. 2021 May 31;16(1):351. doi: 10.1186/s13018-021-02497-0
   PubMed Web of Science ®Google Scholar
• Diez-Perez A, Adachi JD, Agnusdei D, et al. Treatment failure in osteoporosis. Osteoporosis Int. 2012 Dec;23(12):2769–2774.
   PubMed Web of Science ®Google Scholar
• Delmas PD, Vrijens B, Eastell R, et al. Effect of monitoring bone turnover markers on persistence with risedronate treatment of postmenopausal osteoporosis. J Clin Endocrinol Metab. 2007;92(4):1296–1304. doi: 10.1210/jc.2006-1526
   PubMed Web of Science ®Google Scholar
• Mattia L, Davis S, Mark-Wagstaff C, et al. Utility of PINP to monitor osteoporosis treatment in primary care, the POSE study (PINP and osteoporosis in Sheffield evaluation). Bone. 2022 May 1;158. doi: 10.1016/j.bone.2022.116347
   PubMed Web of Science ®Google Scholar
• Vrijens B, De Geest S, Hughes DA, et al. A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol. 2012 May;73(5):691–705.
   PubMed Web of Science ®Google Scholar
• Silverman SL, Nasser K, Nattrass S, et al. Impact of bone turnover markers and/or educational information on persistence to oral bisphosphonate therapy: a community setting-based trial. Osteoporosis Int. 2012 Mar;23(3):1069–1074. doi: 10.1007/s00198-011-1721-z
   PubMed Web of Science ®Google Scholar
• Eastell R, Rosen CJ, Black DM, et al. Pharmacological management of osteoporosis in postmenopausal women: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2019 May 1;104(5):1595–1622. doi: 10.1210/jc.2019-00221
   PubMed Web of Science ®Google Scholar
• Lorentzon M, Branco J, Brandi ML, et al. Algorithm for the use of biochemical markers of bone turnover in the diagnosis, assessment and follow-up of treatment for osteoporosis. Adv Ther. 2019;36(10):2811–2824.
   PubMed Web of Science ®Google Scholar
• Camacho PM, Petak SM, Binkley N, et al. American Association of Clinical Endocrinologists/American College of Endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis-2020 update. Endocr Pract.2020 May;26(Suppl 1):1–46.
   PubMed Web of Science ®Google Scholar
• Lane NE, Saag K, O’neill TJ, et al. Real-world bone turnover marker use: impact on treatment decisions and fracture. Intern Osteoporosis. 2021 May;32(5):831–840. doi: 10.1007/s00198-020-05734-0
   PubMed Web of Science ®Google Scholar
• Paskins Z, Moult A, Corp N, et al. Research priorities regarding the use of bisphosphonates for osteoporosis: a UK priority setting exercise. Osteoporosis Int. 2023 Oct 1;34(10):1711–1718. doi: 10.1007/s00198-023-06806-7
   PubMed Web of Science ®Google Scholar